JNJ-90301900

DRUG4 trials

Sponsors

Johnson & Johnson Enterprise Innovation Inc.

Conditions

Carcinoma, Non-Small-Cell LungLocally Advanced Head & Neck Squamous Cell CarcinomaLocally advanced and unresectable Stage III non-small cell lung cancerSquamous Cell Carcinoma of Head and Neck

Phase 1

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

RecruitingNCT07219212

Johnson & Johnson Enterprise Innovation Inc.Squamous Cell Carcinoma of Head and Neck

Start: 2026-01-26End: 2028-07-14Target: 45Updated: 2026-08-28

Phase 2

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

RecruitingNCT06667908

Johnson & Johnson Enterprise Innovation Inc.Carcinoma, Non-Small-Cell Lung

Start: 2024-12-06End: 2028-12-31Target: 130Updated: 2026-08-28

A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer

RecruitingCTIS2024-518276-32-00

Johnson & Johnson Enterprise Innovation Inc.Locally advanced and unresectable Stage III non-small cell lung cancer

Start: 2025-08-29Target: 25Updated: 2025-11-19

Phase 3

A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma

RecruitingCTIS2024-520386-31-00

Johnson & Johnson Enterprise Innovation Inc.Locally Advanced Head & Neck Squamous Cell Carcinoma

Start: 2025-09-22Target: 194Updated: 2026-01-12